Opioid Drug Abuse Testing Key Topic at Congress
|
By LabMedica International staff writers Posted on 08 Jun 2017 |
Development of new diagnostic procedures for opioid drugs and augmenting communication pathways between laboratory, clinician, and patient are important topics that will be addressed at the July 30 to August 3, 2017, AACC Annual Meeting & Clinical Lab Expo (San Diego, CA, USA).
In the United States - according to data reported in the December 2016 issue of the journal Morbidity and Mortality Weekly Report - opioids accounted for more than two-thirds of all drug overdose deaths in 2015, 15.6% more than the previous year, and drug overdose deaths nearly tripled between 1999 and 2014.
While official agencies and medical groups recommend clinical laboratory tests to support efforts aimed at curbing opioid drug abuse, many physicians may not be fully equipped with the knowledge required to interpret this test data for their patients. To help in this regard, nationally recognized centers, such as the Mayo Clinic (Rochester, MN, USA) have entered the limelight.
Physician requests for assistance in interpreting pain management tests at the Mayo Clinic increased after the [U.S.] Centers for Disease Control and Prevention (Atlanta, GA, USA) issued guidelines in March 2016 recommending urine drug testing before starting patients on opioid therapy and for monitoring them afterward. This guideline and others are driving the testing, but also leading to more confusion in terms of which type of laboratory tests to use - for example, immunoassays versus definitive methods - which specific tests to include, the frequency, and how to interpret those tests.
To help out, the Mayo Clinic now deploys many tools to help providers navigate the nuances of drug testing. Mayo’s online test catalog includes a primer on interpreting drug tests for compliance, along with short “hot topic” videos and other online educational tools.
Other institutions are also rising to the challenge. Vanderbilt University (Nashville, TN, USA) for example, now makes it possible for physicians to request interpretative services at the time they order a test.
In response to the opioid crisis, discussions at the AACC Annual Meeting will emphasize that clinical labs and their physician clients need to work together to stay abreast of drug testing needs in their local communities.
Related Links:
AACC Annual Meeting & Clinical Lab Expo
Mayo Clinic
Centers for Disease Control and Prevention
Vanderbilt University
In the United States - according to data reported in the December 2016 issue of the journal Morbidity and Mortality Weekly Report - opioids accounted for more than two-thirds of all drug overdose deaths in 2015, 15.6% more than the previous year, and drug overdose deaths nearly tripled between 1999 and 2014.
While official agencies and medical groups recommend clinical laboratory tests to support efforts aimed at curbing opioid drug abuse, many physicians may not be fully equipped with the knowledge required to interpret this test data for their patients. To help in this regard, nationally recognized centers, such as the Mayo Clinic (Rochester, MN, USA) have entered the limelight.
Physician requests for assistance in interpreting pain management tests at the Mayo Clinic increased after the [U.S.] Centers for Disease Control and Prevention (Atlanta, GA, USA) issued guidelines in March 2016 recommending urine drug testing before starting patients on opioid therapy and for monitoring them afterward. This guideline and others are driving the testing, but also leading to more confusion in terms of which type of laboratory tests to use - for example, immunoassays versus definitive methods - which specific tests to include, the frequency, and how to interpret those tests.
To help out, the Mayo Clinic now deploys many tools to help providers navigate the nuances of drug testing. Mayo’s online test catalog includes a primer on interpreting drug tests for compliance, along with short “hot topic” videos and other online educational tools.
Other institutions are also rising to the challenge. Vanderbilt University (Nashville, TN, USA) for example, now makes it possible for physicians to request interpretative services at the time they order a test.
In response to the opioid crisis, discussions at the AACC Annual Meeting will emphasize that clinical labs and their physician clients need to work together to stay abreast of drug testing needs in their local communities.
Related Links:
AACC Annual Meeting & Clinical Lab Expo
Mayo Clinic
Centers for Disease Control and Prevention
Vanderbilt University
Latest AACC 2017 News
- Siemens Healthineers Showcases Atellica Solution at AACC 2017
- Ortho Clinical Diagnostics Highlights Immunodiagnostics at Clinical Expo
- Combating Infectious Diseases Key Focus of AACC
- World's First Fully Integrated LC-MS/MS Clinical Analyzer Unveiled
- Clinical Chemistry Analyzer Provides DAU Screening
- Diatron Displays New Hematology Analyzer at UAE Congress
- Microscan Demonstrates Advanced Technology at Scientific Meeting
- AACC Middle East to Be Held in Abu Dhabi
- AACC 2017 Focus on CRISPR and Futuristic Testing Devices
- Keynote Address to Focus on CRISPR/Cas9 Gene Editing
- Winner of Qualcomm Tricorder XPrize Unveiled at AACC
- Annual Meeting Offers Industry Education and Entertainment
Channels
Clinical Chemistry
view channel
Blood Test Enters UK Primary Care Pathway for Earlier Alzheimer’s Diagnosis
Alzheimer’s disease is often first suspected in primary care, yet definitive evaluation frequently depends on specialized imaging or cerebrospinal fluid testing. This creates a persistent gap between disease... Read more
Machine Learning Model Shows Promise for Improving Metanephrine Testing Accuracy
Pheochromocytomas and paragangliomas are rare tumors that form in or near the adrenal glands and cause overproduction of stress hormones. Plasma-free metanephrines are the recommended first-line test,... Read moreMolecular Diagnostics
view channel
AI-Powered Liquid Biopsy Detects Liver Cancer Across Diverse Populations
Liver cancer remains a leading cause of cancer mortality worldwide, with incidence rising alongside the growing burden of metabolic liver disease. Early detection can substantially improve outcomes, yet... Read more
Circular RNAs Enable Noninvasive Cancer Detection and Risk Assessment
Liquid biopsy promises earlier cancer detection and agile treatment monitoring, but robust biomarkers that are stable and disease‑specific remain a hurdle. Circular RNAs (circRNAs) are structurally resilient... Read moreHematology
view channel
Age-Specific CBC Reference Intervals Support Pediatric Diagnosis in Vietnam
Complete blood count (CBC) results underpin pediatric evaluation for anemia, infection, inflammation, and platelet disorders. Yet laboratories in Vietnam have largely relied on reference intervals derived... Read more
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
Minimal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately... Read moreImmunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
New Sensitive Blood Assay Detects Tuberculosis Antigen Directly in Blood
Tuberculosis continues to be a leading global infectious disease, and diagnosis still hinges on sputum samples that many patients cannot produce early in illness. Delays in confirming Mycobacterium tuberculosis... Read more
High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
Testing for tuberculosis remains a persistent global need, with demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies, and public health programs.... Read morePathology
view channel
AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
Bowel cancer is Australia’s fourth most commonly diagnosed cancer and the second leading cause of cancer death, while remaining the third most common cancer worldwide. In stage-two disease, determining... Read more
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channelPartnership Brings Automated Pathology Archiving Solutions to U.S. Labs
Accurate retention and retrieval of pathology blocks and slides underpin timely, reliable cancer diagnoses, yet manual archiving remains labor-intensive and error-prone for many laboratories.... Read more





 Assay.jpg)


